Sarepta Therapeutics
SRPT
366 hedge funds and large institutions have $4.97B invested in Sarepta Therapeutics in 2021 Q1 according to their latest regulatory filings, with 62 funds opening new positions, 141 increasing their positions, 117 reducing their positions, and 145 closing their positions.
21% more repeat investments, than reductions
Existing positions increased: 141 | Existing positions reduced: 117
5.98% less ownership
Funds ownership: 89.78% → 83.79% (-6%)
19% less funds holding
Funds holding: 454 → 366 (-88)
22% less call options, than puts
Call options by funds: $116M | Put options by funds: $149M
57% less first-time investments, than exits
New positions opened: 62 | Existing positions closed: 145
59% less capital invested
Capital invested by funds: $12.1B → $4.97B (-$7.11B)
100% less funds holding in top 10
Funds holding in top 10: 5 → 0 (-5)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Janus Henderson Group
London,
United Kingdom
|
+$212M |
| 2 |
Sands Capital Management
Arlington,
Virginia
|
+$189M |
| 3 |
AIM
ARK Investment Management
St. Petersburg,
Florida
|
+$149M |
| 4 |
Voloridge Investment Management
Jupiter,
Florida
|
+$49.1M |
| 5 |
Bank of New York Mellon
New York
|
+$46.8M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Jennison Associates
New York
|
-$218M |
| 2 |
Fidelity Investments
Boston,
Massachusetts
|
-$148M |
| 3 |
Invesco
Atlanta,
Georgia
|
-$124M |
| 4 |
Artisan Partners
Milwaukee,
Wisconsin
|
-$90.5M |
| 5 |
WRF
Waddell & Reed Financial
Overland Park,
Kansas
|
-$86.9M |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
|
VCG
501
Vantage Consulting Group
Virginia Beach,
Virginia
| – | -$1K | -6 | Closed |
|
|
GRP
502
Global Retirement Partners
San Rafael,
California
| – | -$1K | -5 | Closed |
|
|
BFC
503
Bedel Financial Consulting
Indianapolis,
Indiana
| – | -$1K | -4 | Closed |
|
|
CB
504
CNB Bank
Clearfield,
Pennsylvania
| – | -$1K | -4 | Closed |
|
505
Fifth Third Bancorp
Cincinnati,
Ohio
| – | -$1K | -3 | Closed |
|
|
MCM
506
Manchester Capital Management
Manchester,
Vermont
| – | -$1K | -3 | Closed |
|
|
BWM
507
BerganKDV Wealth Management
Bloomington,
Minnesota
| – | +$185 | +2 | +50% |
|
|
MWM
508
Mascoma Wealth Management
Hanover,
New Hampshire
| – | +$461 | +5 | New |
|
509
Simplex Trading
Chicago,
Illinois
| – | +$3.08M | +33,355 | New |
|
SRPT Hedge Fund Activity: Q1 2021 in Review
366 of the 5,695 institutional investors tracked by Wall St. Rank reported a position in Sarepta Therapeutics (SRPT) for Q1 2021, worth a combined $4.97B — down 59% from $12.1B a quarter earlier.
Sellers outnumbered buyers: 145 funds closed out of SRPT and 62 opened new positions — a net loss of 83 holders — while 117 trimmed existing stakes and 141 added.
The largest buyer was Janus Henderson Group, adding an estimated $212M. The largest seller was Jennison Associates, cutting an estimated $218M.
- 366 institutional investors held Sarepta Therapeutics (SRPT) as of Q1 2021, down from 454 in Q4 2020.
- Funds reported $4.97B of Sarepta Therapeutics stock for Q1 2021, down 59% quarter-over-quarter.
- 62 funds opened new Sarepta Therapeutics positions in Q1 2021 and 145 closed out, a net change of -83 holders.
- The largest Sarepta Therapeutics buyer in Q1 2021 was Janus Henderson Group, an estimated $212M added.
- The largest Sarepta Therapeutics seller in Q1 2021 was Jennison Associates, an estimated $218M sold.
Based on aggregated 13F filings for Q1 2021.